Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia

A Blinded, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) in the Treatment of Iron Deficient Patients With Fibromyalgia

This study investigates the efficacy and safety of an IV iron Injectafer in the treatment of iron deficient patients with fibromyalgia. Eligible subjects will be randomized in a 1:1 ratio to receive Injectafer or Placebo on days 0 and 5. All treated subjects will be followed for efficacy and safety for 42 days.

Study Overview

• Status: Completed
• Conditions: Fibromyalgia; Iron Deficiency
• Intervention / Treatment: Drug: Placebo; Drug: Injectafer

Detailed Description

This is a blinded, randomized, placebo-controlled study. All subjects who meet the inclusion requirements and no exclusion criteria will be entered into an up to 14 day screening phase. Eligible subjects will be randomized in a 1:1 ratio to receive Injectafer or Placebo on days 0 and 5. All treated subjects will be followed for efficacy and safety for 42 days. Subjects will visit the clinic on days 0 and 5 for treatment, and then on days 14, 28, and 42. The subject's participation in the study will be for approximately 42 days from day 0.

• Study Type: Interventional
• Enrollment (Actual): 81
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Tennessee
    • Franklin, Tennessee, United States, 37064
      • Clinical Research Solutions

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female subject's ≥ 18 years of age, able to give informed consent to the study.
• Fibromyalgia diagnosis based on The 2011 modification of the American College of Rheumatology (ACR) 's 2010 preliminary criteria for diagnosing fibromyalgia (2011ModCr)
• A baseline score ≥ 60 on the FIQR
• Subject's current medications to treat fibromyalgia, including pain medicines, anti-depressants, sleep medications must be on a stable dose for at least 30 days.
• Subject's current narcotic medication must be on a stable dose for at least 30 days prior to randomization
• Subjects at risk for pregnancy must have a negative pregnancy test at baseline and be practicing an acceptable form of birth control: have had a hysterectomy or tubal ligation, or otherwise be incapable of pregnancy, or have practiced any of the following methods of contraception for at least one month prior to study entry: hormonal contraceptives, spermicide and barrier, intrauterine device, partner sterility.

Exclusion Criteria:

• Parenteral iron use within 4 weeks prior to screening.
• History of > 10 blood transfusions in the past 2 years.
• Anticipated need for blood transfusion during the study.
• Known hypersensitivity reaction to any component of Injectafer® (Ferric Carboxymaltose).
• Current or acute or chronic infection other than viral upper respiratory tract infection
• Malignancy (other than basal or squamous cell skin cancer or the subject has been cancer free for ≥ 5 years).
• Active inflammatory arthritis (e.g. rheumatoid arthritis, SLE).
• Pregnant or lactating women.
• Severe peripheral vascular disease with significant skin changes.
• Seizure disorder currently being treated with medication.
• Baseline ferritin ≥ 50 ng/mL.
• Baseline TSAT ≥ 20%.
• History of hemochromatosis or hemosiderosis or other iron storage disorders.
• Known positive hepatitis with evidence of active disease.
• Hemoglobin greater than the upper limit of normal.
• Calcium or phosphorous outside the normal range.
• Known positive hepatitis B antigen (HBsAg) or hepatitis C viral antibody (HCV) with evidence of active hepatitis (i.e., AST/ALT greater than the upper limit of normal).
• Known positive HIV-1/HIV-2 antibodies (anti-HIV)
• Received an investigational drug within 30 days before randomization.
• Chronic alcohol or drug abuse within the past 6 months.
• Any other pre-existing laboratory abnormality, medical condition or disease which in view of the investigator participation in this study may put the subject at risk.
• Subject unable to comply with the study requirements.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Injectafer; 15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute	Drug: Injectafer; Other Names: Ferric Carboxymaltose (FCM)
Placebo Comparator: Placebo; 15 cc of Normal Saline IV push at 2 ml/minute	Drug: Placebo; Normal saline solution; Other Names: Saline solution

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of Patients With a ≥13 Point Improvement in FIQR Score	The primary efficacy endpoint was the percentage of subjects who had a ≥13-point improvement in the FIQR from baseline to Day 42.	Day 42

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in BPI, Pain Interference	The short version of the Brief Pain Inventory (BPI) includes front and back body diagrams, 4 pain severity items and 7 pain interference items rated on 0-10 scales (with 0 being the best outcome and 10 being the worst outcome), and a question about percentage of pain relief by analgesics. The Pain Interference Score is calculated by adding the scores for the 7 pain interference questions and then dividing by 7 to give a score out of 10.	Change from Baseline in Brief Pain Inventory Pain Interference Score at Day 42
Change in FIQR Score	The FIQR has 21 individual questions. All questions are based on an 11-point numeric rating scale of 0 to 10, with 10 being 'worst' and all questions are framed in the context of the past 7 days. The summed score for function (range 0 to 90) is divided by 3, the summed score for overall impact (range 0 to 20) is not changed, and the summed score for symptoms (range 0 to 100) is divided by 2. The total FIQR is the sum of the three modified domain scores.	Change from Baseline in FIQR score at Day 42
Change in BPI, Pain Severity	The short version of the Brief Pain Inventory (BPI) includes front and back body diagrams, 4 pain severity items and 7 pain interference items rated on 0-10 scales (with 0 being the best outcome and 10 being the worst outcome), and a question about percentage of pain relief by analgesics. The Pain Severity Score is calculated by adding the scores for the 4 pain severity questions and then dividing by 4 to give a severity score out of 10.	Change from Baseline in Brief Pain Inventory Pain Severity Score at Day 42
Change in Fatigue Visual Numeric Scale	Scores range from 0 to 10, with the higher score indicating more fatigue.	Change from Baseline in Fatigue Visual Numeric Scale at Day 42
Change in Iron Indices, Serum Ferritin		Change from Baseline in Iron Indices, Serum ferritin at Day 42
Change in Iron Indices - Transferrin Saturation		Change from baseline in Iron Indices, Transferrin saturation, at Day 42

Collaborators and Investigators

• Sponsor: American Regent, Inc.

Publications and helpful links

General Publications

• Boomershine CS, Koch TA, Morris D. A Blinded, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Ferric Carboxymaltose in Iron-Deficient Patients with Fibromyalgia. Rheumatol Ther. 2018 Jun;5(1):271-281. doi: 10.1007/s40744-017-0088-9. Epub 2017 Nov 17.

Study record dates

Study Major Dates

• Study Start: March 1, 2015
• Primary Completion (Actual): October 1, 2015
• Study Completion (Actual): March 1, 2016

Study Registration Dates

• First Submitted: April 1, 2015
• First Submitted That Met QC Criteria: April 3, 2015
• First Posted (Estimate): April 6, 2015

Study Record Updates

• Last Update Posted (Actual): February 20, 2018
• Last Update Submitted That Met QC Criteria: January 22, 2018
• Last Verified: January 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Muscular Diseases; Neuromuscular Diseases; Fibromyalgia; Myofascial Pain Syndromes
• Other Study ID Numbers: 1VIT14038

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes